STEPS TAKEN AFTER THE MARKETING AUTHORISATION 
For procedures finalised after 1 November 2004 please refer to module 8B. 
 
 
 
 
 
 
On  18  December  1998,  the  Marketing  Authorisation  Holder  (MAH)  applied  for  a  Type  I 
Variation  in  accordance  with  Commission  Regulation  (EC)  542/95,  as  amended.  The  MAH 
applied for an additional alternative manufacturer  for one step of the manufacturing process of 
the active substance. On 20 January 1999, the EMEA issued a Notification that the variation is 
accepted and does not require any amendment to the Community Marketing Authorisation.. 
On 06 January 1999, the Marketing Authorisation Holder (MAH) applied for a Type I Variation 
in accordance with Commission Regulation (EC) 542/95, as amended. The MAH applied for an 
alternative  manufacturer  of  the  active  substance.  On  05  February  1998,  the  EMEA  issued  a 
Notification as the variation is accepted and does not require any amendment to the Community 
Marketing Authorisation. 
On  18  January  1999,  the  Marketing  Authorisation  Holder  (MAH)  applied  for  two  Type  I 
Variation  in  accordance  with  Commission  Regulation  (EC)  542/95,  as  amended.  The  MAH 
applied  for  an  increase  of  the  size  of  the  batch  of  the  finished  product  and  a  change  of  the 
manufacturing  site  for  all  of  the  manufacturing  process  of  the  medicinal  product.  on  19 
February 1999, the EMEA issued two Notifications that the variations are accepted and do not 
require any amendment to the Community Marketing Authorisation. 
Between 1 June and 21 December 1999, the EMEA issued Notifications for the approval of four 
type I variations concerning; 
- 
- 
- 
- 
change in specification of starting material or intermediate used in the manufacture of the 
active substance, 
change  in  supplier  of  an  intermediate  compound  used  in  manufacture  of  the  active 
substance, 
change in the manufacture of the medicinal product, 
minor change in manufacturing process of the active substance. 
These variations did not require any amendment to the Commission Decision. 
Between  26  February  1999  and  22  December  1999,  the  Marketing  Authorisation  Holder 
requested  to  introduce  changes  to    aspects  of  the  labelling  not  connected  to  the  Summary  of 
Product  Characteristics,  by  means  of  three  Notifications  under  Article  10(3)  of  Directive 
92/27/EEC. Following EMEA’s Notifications on 26 March, 11 November 1999 and 18 January 
2000,  the  European  Commission  amended  the  Decision  (Annex  III  B)  on  7  May  1999,  3 
February 2000 and 24 March 2000, respectively. 
On 13 April 2000, the Marketing Authorisation Holder submitted a type II variation application 
in accordance with Article 6 of Commission Regulation (EC) No.542/95 of 10 March 1995, as 
amended.  The  Marketing  Authorisation  Holder  applied  for  an  update  of  the  SPC  and  PL 
accordingly to recently approved changes for the monotherapy product and post-marketing data. 
On  27  July  2000,  the  CPMP  approved  the  variation.  The  variation  required  amendments  in 
annex  I  and  III  B  of  the  Commission  Decision.  The  European  Commission  amended  the 
Decision on 16 November 2000. 
1/3 
   EMEA 2004 
 
  
 
 
 
 
 
 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification
1 
Notification/ 
Opinion 
issued on 2 
Change in test procedure for starting material/intermediate used in 
manuf. of active substance 
Update of Summary of Product Characteristics and Package Leaflet 
Changes to comply with supplements to pharmacopoeias 
Change following modification(s) of the manufacturing 
authorisation(s) 
Minor change of manufacturing process of the active substance 
Update of Summary of Product Characteristics and Package Leaflet 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Change in the name and/or address of the marketing authorisation 
holder 
Replacement of an excipient with a comparable excipient 
Change following modification(s) of the manufacturing 
authorisation(s) 
Change in test procedure for starting material/intermediate used in 
manuf. of active substance 
Extension of shelf-life as foreseen at time of authorisation 
Change in test procedure for starting material/intermediate used in 
manuf. of active substance 
Minor changes in manufacture of the medicinal product 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Minor change of manufacturing process of the active substance 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Extension of shelf-life or retest period of the active substance 
Change in or addition of manufacturer(s) of active substance 
Update of Summary of Product Characteristics and Package Leaflet 
Minor change of manufacturing process of the active substance 
Minor change of manufacturing process of the active substance 
Change or addition of a new pharmaceutical form 
Renewal 
Change in supplier of an intermediate compound used in 
manufacture of the active substance 
Minor change in the manufacturing process of the active substance 
Update of Summary of Product Characteristics and Package Leaflet 
Change in manuf. of active substance without Ph. Eur. certificate - 
change in manuf. Site 
Update of Summary of Product Characteristics and Package Leaflet 
Change in BR/QC testing - repl./add. of batch control/testing site 
and replacement/add. of manufacturing site: All other manufacturing 
operations ex. batch release 
Minor change in the manufacturing process of the active substance 
Change in BR/QC testing - repl./add. manuf. responsible for BR - 
not incl. BC/testing 
Replacement/add. of manufacturing site: Secondary packaging site 
I/13 
II/14 
I/15 
I/16 
I/17 
II/18 
I/19 
I/20 
I/21 
I/22 
I/23 
I/24 
I/25 
I/26 
I/27 
I/28 
I/29 
N/30 
N/31 
I/32 
N/33 
N/34 
I/35 
I/36 
II/37 
I/38 
I/39 
X/40 
R/41 
I/42 
I/43 
II/44 
IB/45 
II/46 
IB/47 
IB/48 
IA/49 
IA/50 
I 
II 
I 
I 
I 
II 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
N 
N 
I 
N 
N 
I 
I 
II 
I 
I 
X 
R 
I 
I 
II 
IB 
II 
IB 
IB 
IA 
IA 
Commission 
Decision 
Issued/amen
ded on 
- 
23.04.01 
- 
- 
- 
10.04.02 
08.10.01 
08.10.01 
19.02.02 
19.02.02 
- 
26.02.02 
08.03.02 
21.11.00 
14.12.00 
20.03.01 
04.04.01 
26.04.01 
20.09.01 
13.07.01 
13.07.01 
20.09.01 
20.09.01 
20.09.01 
12.10.01 
22.12.01 
10.04.02 
02.05.02 
20.02.02 
10.04.02 
05.06.02 
07.06.02 
18.04.02 
20.04.02 
18.06.02 
28.06.02 
03.12.02 
15.01.03 
19.12.02 
17.01.03 
17.01.03 
07.03.03 
04.04.03 
16.05.03 
21.03.03 
23.04.03 
26.06.03 
11.06.03 
12.06.03 
22.10.03 
25.09.03 
31.10.03 
10.11.03 
16.09.04 
14.04.04 
03.06.04 
20.04.04 
01.07.04 
30.06.04 
30.06.04 
01.04.03 
25.04.03 
02.10.03 
26.06.03 
26.06.03 
02.03.04 
04.12.03 
12.11.03 
- 
28.10.04 
- 
02.08.04 
- 
- 
- 
- 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
2/3 
   EMEA 2004 
 
                                                           
 
 
 
 
 
 
 
and change in BR/QC testing - repl./add. manuf. responsible for BR 
- not incl. BC/testing 
Change in manuf. of active substance without Ph. Eur. certificate - 
change in manuf. Site 
Minor change in the manufacturing process of the active substance 
Change in batch size of active substance or intermediate - up to 10-
fold 
IB/51 
IB/53 
IA/54 
IB 
IB 
IA 
28.07.04 
10.08.04 
17.09.04 
- 
- 
- 
3/3 
   EMEA 2004 
 
 
 
 
 
 
 
    
 
 
